CCR2 and breast carcinoma: These and similar findings led researchers to investigate whether CCL2 inhibition could be a feasible treatment target, and resulting tests with propagermanium (PG, a CCR2 inhibitor) (118, 119) did in fact demonstrate great effectiveness for preventing metastasis, translating to improved breast cancer outcomes (84).